Trump
signs executive order to boost U.S. drug manufacturing
Send a link to a friend
[August 07, 2020]
By Jeff Mason and Andrea Shalal
CLYDE, Ohio/WASHINGTON (Reuters) -
President Donald Trump on Thursday signed an executive order aimed at
boosting U.S. production of medicines and medical equipment, lowering
drug prices and protecting the United States against shortfalls in a
future pandemic.
|
Trump said the order would also support advanced manufacturing
processes that would benefit U.S. pharmaceutical companies.
The long-awaited measure includes a "Buy America" provision
mandating federal purchases of certain medical supplies and
equipment deemed essential and moves to remove regulatory hurdles to
approval of new U.S. drugs, the Republican president told workers at
a Whirlpool <WHR.N> washing machine factory in Clyde, Ohio.
The order had been expected for months as part of a drive by the
Trump administration to pull back supply chains from China.
"As we've seen in this pandemic, the United States must produce
essential equipment, supplies and pharmaceuticals for ourselves. We
cannot rely on China and other nations across the globe, that could
one day deny us products in a time of need," Trump said. "We have to
be smart."
In wide-ranging remarks, Trump took aim at China's trade policies
and blasted presumptive Democratic presidential nominee Joe Biden
and former President Barack Obama for failing to recognize the
threat posed by China to U.S. manufacturing.
"During the course of the next four years, we will bring our
pharmaceutical and medical supply chains home," he said. "And we'll
end reliance on China just like we did with the washers and dryers
... we'll be making our product here."
[to top of second column] |
U.S. companies were skeptical about the order as it evolved, warning that it
could trigger potential backlash from China and other suppliers at a time when
more than 1,000 people a day are dying of COVID-19 in the United States.
Senior White House adviser Peter Navarro said it was critical to act now to
prevent future crises and ensure sufficient demand so U.S. companies could
affordably manufacture pharmaceuticals at home, ending their reliance on key
ingredients and supplies from China.
Navarro said the order would also crack down on internet sales of counterfeit
medicines, many of which he said came from China.
The Buy America provisions would require the Department of Health and Human
Services, the U.S. military and the Veterans Administration to procure only
U.S.-made goods to meet certain essential needs, Navarro said.
The order also directs the U.S. Food and Drug Administration and the
Environmental Protection Agency to give priority status to U.S. drug ingredient
manufacturers during their regulatory review process.
(Reporting by Andrea Shalal and Jeff Mason; additional reporting by Susan Heavey;
editing by Jonathan Oatis and Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |